Evidence-based medicine and recommendations for patient diagnosis and treatment are evolving. General suggestions are shifting toward an individual focus, as technological advancements enable the detection of unique patterns and ‘one size fits all’ no longer has a place. Emerging health technology developments offer valuable tools for individualising patients’ particular problems and follow-up. There are numerous preventative programmes aimed at reducing the development of allergy diseases, but no generalizable and conclusive findings have been obtained as of yet. Both omics and molecular diagnostics have given the foundation for distinguishing patient groups, allowing for the prediction of severity as well as recommending suitable therapy. This study will look at several cases that are contributing to the current state of affairs. Precision medicine entails individualised patient care, the prediction of a successful therapy, the potential prevention of a disease and its progression when present, and the crucial active engagement of the patient in the planning and direction of the approach and management. The greatest difficulty in adopting precision medicine will be making those improvements available to everyone at a reasonable cost.

Technology and medical advances are aimed at assisting all patients worldwide by giving evidence for specific diseases that must be carefully considered, involving the patient’s decision while treating, forecasting, and preventing disease. Our goal should be to have precision medicine available at all times and in all places.

Reference: https://journals.lww.com/co-allergy/Abstract/2019/02000/Will_precision_medicine_be_available_for_all.13.aspx

Author